Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study

Krauss, 2011, Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models, Exp Eye Res, 93, 250, 10.1016/j.exer.2011.03.001 Nathanson, 1992, Nitrovasodilators as a new class of ocular hypotensive agents, J Pharmacol Exp Ther, 260, 956 Kotikoski, 2002, Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP, J Ocul Pharmacol Ther, 18, 11, 10.1089/108076802317233171 Schuman, 1994, Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys, Exp Eye Res, 589, 99, 10.1006/exer.1994.1199 Heyne, 2013, Effect of nitric oxide on anterior segment physiology in monkeys, Invest Ophthalmol Vis Sci, 54, 5103, 10.1167/iovs.12-11491 Ota, 2007, The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice, Br J Ophthalmol, 91, 673, 10.1136/bjo.2006.105585 Aptel, 2008, Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials, J Glaucoma, 17, 667, 10.1097/IJG.0b013e3181666557 Rouland, 2013, Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma, Br J Ophthalmol, 97, 196, 10.1136/bjophthalmol-2012-302121 Wizemann, 1980, Organic nitrate therapy in glaucoma, Am J Ophthalmol, 90, 106, 10.1016/S0002-9394(14)75085-8 Diestelhorst, 1991, The effect of isosorbide-mononitrate eye drops on the human intraocular pressure and aqueous humor dynamics, Int Ophthalmol, 15, 259, 10.1007/BF00171028 Garway-Heath, 2015, Latanoprost for open-angle glaucoma (UKGTS): a randomized, multicenter, placebo-controlled trial, Lancet, 385, 1295, 10.1016/S0140-6736(14)62111-5 Lei, 2015, Aqueous humor outflow physiology in NOS3 knockout mice, Invest Ophthalmol Vis Sci, 56, 4891, 10.1167/iovs.15-16564 Chang, 2015, Role of nitric oxide in murine conventional outflow physiology, Am J Physiol Cell Physiol, 309, C205, 10.1152/ajpcell.00347.2014 2014 Lütjen-Drecoll, 1988, Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2a, Exp Eye Res, 47, 761, 10.1016/0014-4835(88)90043-7 Gabelt, 1989, Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey, Exp Eye Res, 49, 389, 10.1016/0014-4835(89)90049-3 Nilsson, 1989, Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey, Exp Eye Res, 48, 707, 10.1016/0014-4835(89)90011-0 Toris, 1993, Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes, Ophthalmology, 100, 1297, 10.1016/S0161-6420(93)31484-3 Lindsey, 1997, Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro, Invest Ophthalmol Vis Sci, 38, 2214 Schachtschabel, 2000, The mechanism of action of prostaglandins in uveoscleral outflow, Curr Opin Ophthalmol, 11, 112, 10.1097/00055735-200004000-00008 Gaton, 2001, Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment, Arch Ophthalmol, 119, 1165, 10.1001/archopht.119.8.1165 Richter, 2003, Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide, Invest Ophthalmol Vis Sci, 44, 4419, 10.1167/iovs.02-1281 Wiederholt, 1994, Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide, Invest Ophthalmol Vis Sci, 35, 2515 Schneemann, 2002, Nitric oxide/guanylate cyclase pathways and flow in anterior segment perfusion, Graefes Arch Clin Exp Ophthalmol, 240, 936, 10.1007/s00417-002-0559-7 Kotikoski, 2003, Nitric oxide and cyclic GMP enhance aqueous humor outflow facility in rabbits, Curr Eye Res, 26, 119, 10.1076/ceyr.26.2.119.14511 Dismuke, 2014, Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility, Exp Eye Res, 120, 28, 10.1016/j.exer.2013.12.012 Cavet, 2014, Nitric oxide (NO): an emerging target for the treatment of glaucoma, Invest Ophthalmol Vis Sci, 55, 5005, 10.1167/iovs.14-14515 Cavet, 2015, Regulation of endothelin-1– induced trabecular meshwork cell contractility by latanoprostene bunod, Invest Ophthalmol Vis Sci, 56, 4108, 10.1167/iovs.14-16015 Weinreb, 2015, A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study, Br J Ophthalmol, 99, 738, 10.1136/bjophthalmol-2014-305908 Weinreb, 2016, Latanoprostene bunod 0.024% vs timolol maleate 0.5% in the treatment of open-angle glaucoma or ocular hypertension: the APOLLO study, Ophthalmology, 123, 965, 10.1016/j.ophtha.2016.01.019 Higginbotham, 2010, Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study, Arch Ophthalmol, 128, 165, 10.1001/archophthalmol.2009.384 Feldman, 2003, Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension, J Ocul Pharmacol Ther, 19, 23, 10.1089/108076803762718088 Zhang, 2001, Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension, Br J Ophthalmol, 85, 983, 10.1136/bjo.85.8.983 Alm, 1997, Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States, Surv Ophthalmol, 41, S105, 10.1016/S0039-6257(97)80016-1 Kass, 2002, The Ocular Hypertension Treatment Study: a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open angle glaucoma, Arch Ophthalmol, 120, 701, 10.1001/archopht.120.6.701 Heijl, 2002, Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial, Arch Ophthalmol, 120, 1268, 10.1001/archopht.120.10.1268 Leske, 2003, Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial, Arch Ophthalmol, 121, 48, 10.1001/archopht.121.1.48 Chauhan, 2008, Canadian Glaucoma Study Group. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma, Arch Ophthalmol, 126, 1030, 10.1001/archopht.126.8.1030 Heijl, 2015, Glaucoma treatment: by the highest level of evidence, Lancet, 385, 1264, 10.1016/S0140-6736(14)62347-3 Orme, 2010, Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension, Curr Med Res Opin, 26, 511, 10.1185/03007990903498786